Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2004

View Archived Issues

Beta adrenergic receptor targeted for treatment of male sexual dysfunction

Promising results of an HCV E1-based vaccine in hepatitis C patients

NPS Pharmaceuticals announces phase III clinical results for Preos in osteoporosis

Potent syncretic antimitotic agent by CombinatoRx

Novel bifunctional small molecule inhibitor to treat neurodegenerative diseases

Potassium channel openers for migraine and neuropathic pain from BMS

BMS-554216, a prodrug of BMS-204352, shows improved pharmacokinetics

MIV-150/Carraguard microbicide demonstrates encouraging preclinical results

Eisai to acquire Elan's Zonegran rights

Schering-Plough signs letter of intent for rights to garenoxacin

Axcan receives European marketing approval for Photobarr PDT

GenVec, PATH's MVI and NMRC expand malaria vaccine efforts

Guilford regains NAALADase inhibitor rights from Pfizer

Results from European phase III trial of Polyphenon E Ointment

GlaxoSmithKline and Theravance to form strategic alliance

Lupin to promote Zymar to U.S. pediatricians

Enrollment completed in second pivotal trial for Neurodex

Final statistical plan agreed for two pivotal Targretin trials

Intravenous Remodulin sNDA accepted for review

New phase I trial studies safety and immunogenicity of Vical's CMV vaccine

Kissei patent covers SGLT1 inhibitors for diabetes, obesity, etc.

Novel PARP inhibitors emerge from research at Kyorin

Cephalosporin derivatives with activity against MRSA disclosed

Ono discovers a novel series of PPAR inhibitors

Antiviral pyrazine derivatives designed by Toyama

Pfizer patent claims combinations of alpha-2-delta ligand/PDEV inhibitor for treatment of pain

Radioimmunotherapy with 131I-cG250 assessed in renal cell carcinoma

WX-G250 plus IFNalpha-2a reported safe and effective in renal cell carcinoma

OM-89 reduces the incidence of urinary tract infections in women

Ono claims use of ornoprostil to reduce diclofenac side effects, improve activity

Alfuzosin reduces need for surgery in acute urinary retention

CHIR-124, a novel small-molecule quinolone-based inhibitor of the CHK1 checkpoint

Ki-23057, a potent, metabolically stable inhibitor of FGFR2 characterized by Kirin

Pfizer presents data on PD-0325901, a more potent and pharmaceutically improved analogue of CI-1040

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...